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Abstract
Background Ethnic disparities have been reported in cardiovascular disease. However, ethnic disparities in takotsubo syn-
drome (TTS) remain elusive. This study assessed differences in clinical characteristics between Japanese and European TTS 
patients and determined the impact of ethnicity on in-hospital outcomes.
Methods TTS patients in Japan were enrolled from 10 hospitals and TTS patients in Europe were enrolled from 32 hospi-
tals participating in the International Takotsubo Registry. Clinical characteristics and in-hospital outcomes were compared 
between Japanese and European patients.
Results A total of 503 Japanese and 1670 European patients were included. Japanese patients were older (72.6 ± 11.4 years 
vs. 68.0 ± 12.0 years; p < 0.001) and more likely to be male (18.5 vs. 8.4%; p < 0.001) than European TTS patients. Physical 
triggering factors were more common (45.5 vs. 32.0%; p < 0.001), and emotional triggers less common (17.5 vs. 31.5%; 
p < 0.001), in Japanese patients than in European patients. Japanese patients were more likely to experience cardiogenic 
shock during the acute phase (15.5 vs. 9.0%; p < 0.001) and had a higher in-hospital mortality (8.2 vs. 3.2%; p < 0.001). 
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However, ethnicity itself did not appear to have an impact on in-hospital mortality. Machine learning approach revealed that 
the presence of physical stressors was the most important prognostic factor in both Japanese and European TTS patients.
Conclusion Differences in clinical characteristics and in-hospital outcomes between Japanese and European TTS patients 
exist. Ethnicity does not impact the outcome in TTS patients. The worse in-hospital outcome in Japanese patients, is mainly 
driven by the higher prevalence of physical triggers.
Trial Registration URL: https:// www. clini caltr ials. gov; Unique Identifier: NCT01947621.
Keywords Takotsubo syndrome · Broken heart syndrome · Ethnicity · Race
Introduction
Takotsubo syndrome (TTS) is characterized by acute left 
ventricular (LV) systolic dysfunction, which is often trig-
gered by emotional or physical stressors [1]. The condition 
was first reported from Japan in 1990 and the terminology 
derived from a Japanese octopus trap known as takotsubo 
because the LV in TTS mimics the shape of it [2, 3]. TTS 
was largely unknown outside Japan until the first reports 
from Europe and the US were published in the late 90 s 
[4, 5]. Since then, TTS has been reported from all conti-
nents, in both sexes and in different ethnic groups [6–11]. 
Although TTS was initially considered to be harmless, it 
is now known that it has a wide range of presentations and 
outcomes, depending on the triggering factor [12]. It may 
even be associated with life-threatening complications, with 
outcomes comparable to those of acute coronary syndromes 
[12–14].
Ethnic and geographic disparities are known to exist in 
many cardiovascular diseases [15, 16]. These differences 
may be related to socioeconomic factors, healthcare sys-
tems, or genetic background, but there is no clear evidence 
in support of such speculation. To date, no large head-to-
head comparison between different ethnic and geographic 
groups has been conducted in the field of TTS research. Lit-
tle is known about ethnic differences in outcomes in TTS, 
especially between Asian and European patients [17].
The present study aimed to investigate differences in 
clinical characteristics and in-hospital outcomes between 
Japanese and European TTS patients and to evaluate the 
impact of ethnic background on outcomes.
Methods
Patients and inclusion criteria
The Japanese TTS patients were enrolled from 10 different 
hospitals, while the European TTS patients were enrolled 
from the University Hospital Zurich and 31 other collabo-
rating hospitals in 9 countries (Austria, Czech Republic, 
Finland, France, Germany, Italy, Poland, Switzerland, and 
the UK) (Fig. 1). Data were collected from January 1, 2011, 
through October 31, 2017, and patients with unknown eth-
nicity were excluded from the present analysis. All patients 
were diagnosed according to the InterTAK Diagnostic Cri-
teria [18]:.
1) Transient LV wall motion abnormality presenting as 
apical ballooning or midventricular, basal, or focal wall 
motion abnormalities. The wall motion abnormality usu-
ally extends beyond a single epicardial coronary artery 
distribution; however, in rare cases, especially in focal 
TTS, wall motion abnormality may be limited to a sin-
gle coronary artery distribution. TTS patients who died 
during the acute phase, before complete recovery of LV 
wall motion, were also eligible for inclusion.
2) TTS event is typically triggered by emotional or physi-
cal, or combined stress. However, this is not obligatory. 
Neurologic disorders or pheochromocytoma may also 
serve as triggers.
3) Appearance of new electrocardiographic (ECG) abnor-
malities. Occasionally, there may not be any electrocar-
diographic changes.
4) Occurrence of moderate elevations of cardiac biomark-
ers (troponin and/or creatine kinase). Elevation of brain 
natriuretic peptide is common.
5) Coexisting significant coronary artery disease, which is 
not related to the wall motion abnormality, does not rule 
out TTS.
6) No evidence of infectious myocarditis.
The study protocol was approved by the respective local 
ethics committees or institutional review boards at each 
collaboration site. Due to the, in part, retrospective nature 
of the study, the ethics committees of most study centers 
waived the need for informed consent. At centers where the 
ethics committees or institutional review boards required 
informed consent, formal written consent was obtained from 
all included patients or their surrogates.
Clinical characteristics and in‑hospital outcomes
We compared demographic data, clinical characteristics, 
triggering factors, taktosubo type, laboratory values, ECG 
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findings, vital signs, hemodynamic findings, cardiovascular 
risk factors, and medications prescribed (before admission 
and at discharge) between the Japanese and European TTS 
cohorts. Acute cardiac care treatment (use of catecholamine 
and intra-aortic balloon pump [IABP]) and in-hospital com-
plications (cardiogenic shock and death) were also compared 
between the two groups.
Statistical analysis
Continuous data were summarized as means ± standard devi-
ations or medians and interquartile ranges. Categorical vari-
ables were summarized as numbers and percentages. Com-
parisons of characteristics between different groups were 
performed using the unpaired t test or the Mann–Whitney 
U test for continuous variables and the Pearson chi-squared 
test for categorical variables. Variables that were statistically 
significant on univariate analysis were included in multivari-
ate models, using in-hospital mortality as an endpoint. Two 
different models (Model I: without ethnicity as a covariate 
and Model II with ethnicity as a covariate) were used. The 
Hosmer–Lemeshow test for goodness of fit was performed 
for both logistic regression models. To compare these two 
models, and to clear any doubts about which model is more 
appropriate, three different statistical approaches were used. 
First, the Brier score was used to quantify the accuracy of 
risk predictions of our two logistic regression models by 
comparing predicted risks with observed outcomes at the 
individual level. The lower the Brier score is for a set of 
predictions, the better the predictions are calibrated. Sec-
ond, classification performance was evaluated by use of 
receiver operating characteristic (ROC) curves. Third, the 
predictiveness curve was calculated [19]. The predictive-
ness curve is a plot of the cumulative percentage of indi-
viduals to the predicted risks. The cumulative percentage 
indicates the percentage of individuals with predicted risk 
equal to, or lower than, the risk value. The predictiveness 
curve also displays essential information about risk that is 
not displayed by the ROC curve [19]. The Delong [20] as 
well as the Venkatraman test [21] were used to compare 
the AUCs for equivalence (equivalence bound 5%) and then 
for equality ((AUCII—AUCI) = 0) (condition = in-hospital 
death). To evaluate the influence of each factor on in-hospi-
tal death, we used a radial basis function network (RBF-net) 
[22]. RBF networks are artificial neural networks that use 
radial basis functions as activation functions. They are pri-
marily used for regression or function approximation. The 
Bayesian Information Criterion (BIC) determines the num-
ber of units in the hidden layer. The "best" number of hidden 
units is the one that yields the smallest BIC in the training 
data. We used normalized Gaussian radial basis functions 
as activation functions for the hidden layer. For the output 
layer, we used the identity function as the activation func-
tion; thus, the output units are simply weighted sums of the 
hidden units. The output of the network (in-hospital death) 
is, therefore, a linear combination of normalized Gaussian 
radial basis functions of the inputs and neuron parameters. 
Decision trees such as Classification And Regression Trees 
Fig. 1  Collaborators from Japan 
and Europe. Participants in this 
study included 10 centers from 
Japan and 32 centers from 9 
countries in Europe (includ-
ing Austria, Czech Republic, 
Finland, France, Germany, Italy, 
Poland, Switzerland, and the 
UK)
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(CART) or exhaustive CHi-squared Automatic Interaction 
Detector (CHAID), were used in addition as a nonparametric 
supervised learning method for classification and regression. 
Decision trees are adaptive in at least three aspects: they 
(1) adapt to favorable conditions near the Bayes decision 
boundary; (2) focus on data distributed on lower dimen-
sional manifolds, and (3) reject irrelevant features.
All tests were two sided and statistical significance was 
defined as p < 0.05. Statistical analyses were performed 
using IBM SPSS Statistics, version 25.0 (IBM Corp., 
Armonk, NY, USA) and R, version 3.5 (https:// cran.r- proje 
ct. org/).
Results
A total of 503 Japanese TTS patients and 1670 European 
TTS patients were included in this study. Table 1 presents 
a comparison of clinical characteristics between Japanese 
and European patients. The proportion of male patients was 
significantly higher in the Japanese cohort (18.5 vs. 8.4%; 
p < 0.001). Japanese patients were older (72.6 ± 11.4 vs. 
68.0 ± 12.0 years; p < 0.001) and had lower body mass index 
(21.0 ± 3.6 vs. 24.8 ± 4.6 kg/m2; p < 0.001) than European 
patients. Japanese patients had lower prevalence of hyperten-
sion (52.7 vs. 66.3%; p < 0.001), current smoking (15.2 vs. 
18.7%; p < 0.001), and higher prevalence of diabetes mellitus 
(18.1 vs. 13.5%, p = 0.011) than European patients. Troponin 
(median factor increase of the upper limit of normal, 16.78 
vs. 7.67; p < 0.001) and brain natriuretic peptide plasma 
levels (median factor increase of the upper limit of normal, 
13.14 vs. 5.72; p < 0.001) at hospital admission were signifi-
cantly higher in Japanese patients. ST-segment elevation on 
admission was more common in Japanese patients than in 
European patients (70.3 vs. 45.0%; p < 0.001). Left ventricu-
lar ejection fraction (LVEF) on admission was significantly 
higher in Japanese than in European patients (44.5 ± 13.3 
vs. 41.8% ± 11.2%; p < 0.001). Japanese patients were more 
likely to have physical triggers (45.5 vs. 32.0%; p < 0.001), 
and less likely to have emotional triggers (17.5 vs. 31.5%; 
p < 0.001) than European patients. Details on triggering 
factors are shown in Supplementary Fig. 1. Before admis-
sion, Japanese patients were more likely to be using cal-
cium-channel antagonists (25.5 vs. 7.2%; p < 0.001), while 
European patients were more likely to be using angiotensin-
converting enzyme inhibitors/angiotensin-receptor blockers 
(39.4 vs. 30.8%; p = 0.001) and beta-blockers (30.9 vs. 7.9%; 
p < 0.001). The same trend in medications prescribed was 
seen at discharge (Table 1).
While in-hospital Japanese patients were more likely to 
experience cardiogenic shock (15.5 vs. 9.0%; p < 0.001) and 
more likely to receive treatment with catecholamines (14.1 
vs. 10.3%; p = 0.016) or IABP (5.6 vs. 2.1%; p < 0.001) to 
maintain hemodynamic stability. In-hospital mortality was 
significantly higher in Japanese patients than in European 
patients (8.2 vs. 3.2%; p < 0.001).
To evaluate the influence of ethnicity on in-hospital death, 
we first used the two different multiple logistic regression 
models (Table 2). The Hosmer–Lemeshow test for goodness 
of fit demonstrated no evidence of poor fit for Models I and 
II (p = 0.26 and = 0.39, respectively). The Brier score was 
0.038 for Model I and 0.037 for Model II, demonstrating 
that these two models were nearly identical with respect to 
risk predictions. On ROC analysis, the area under the curve 
(AUC) (95% confidence interval) was 0.81 (0.78–0.86) for 
Model I and 0.83 (0.78–0.88) for Model II. The comparisons 
of ROC curves to test for statistically significant differences 
between the areas under the ROC curves AUCII and AUCI 
using Venkatraman and DeLong tests, demonstrate again 
that these two models had an identical classification per-
formance ((AUCII—AUCI) = 0 for condition = in-hospital 
death; Venkatraman p = 0.15; Delong p = 0.052). The pre-
dictiveness curves of both models were also almost identi-
cal (Fig. 2). Both predictiveness curves calculated the risk 
of in-hospital death as ≤ 10% for around 90% of the study 
population.
Radial Basis Function Networks and CART were applied 
to analyze the effect of various variables on in-hospital death 
in the Japanese and European cohorts. The normalized 
importance of the respective variables for the Japanese and 
European cohorts is summarized in Supplementary Figs. 2 
and 3. Physical stress was the most important prognostic 
factor for in-hospital mortality in both cohorts. The second 
most important prognostic factor was LVEF by both CART 
and RBF-nets for Japanese patients, while it was white blood 
cell count by CART or heart rate by RBF-nets for Euro-
pean patients. The in-hospital mortality rate in TTS patients 
without physical stress (n = 1410; 64.9%) was 1.7%, with no 
significant difference between the Japanese (n = 274) and 
European (n = 1136) cohorts (2.6 vs. 1.5%, p = 0.22) (Fig. 3). 
Discussion
This study aimed to investigate differences in clinical and 
demographic characteristics and in-hospital outcomes 
between Japanese and European TTS patients and to deter-
mine whether ethnicity affects outcomes. The main find-
ings were as follows: (2) Japanese patients were more likely 
to have physical triggers, and less likely to have emotional 
triggers; (3) Japanese patients required more often catecho-
lamines and/or IABP to maintain hemodynamic stability; 
and (4) Japanese patients had higher in-hospital mortality, 
although ethnicity per se did not appear to have an impact 
on the higher mortality.
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Table 1  Comparisons of clinical characteristics between Japanese and European patients with TTS
Characteristic Japanese patients European patients p value
n = 503 n = 1670
Demographics
 Female sex 410 (81.5) 1529 (91.6)  < 0.001
 Age, mean (SD), y 72.6 (11.4), n = 503 68.0 (12.0), n = 1670  < 0.001
 BMI, mean (SD), kg/m2 21.0 (3.6), n = 470 24.8 (4.6), n = 1239  < 0.001
Triggers
 Physical trigger 229 (45.5) 534 (32.0)  < 0.001
 Emotional trigger 88 (17.5) 526 (31.5)  < 0.001
 Both emotional and physical trigger 8 (1.6) 122 (7.3)  < 0.001
 No evident trigger 178 (35.4) 488 (29.2) 0.009
Takotsubo type
 Apical type 358 (71.2) 1169 (70.0) 0.61
Cardiac biomarkers on admission, median (IQR)
 Troponin, fold ULN* 16.78 (4.58–48.94), n = 337 7.67 (2.50–21.15), n = 1233  < 0.001
 Creatine kinase, fold ULN 0.96 (0.47–1.83), n = 484 0.87 (0.56–1.45), n = 1204 0.62
 BNP, fold ULN† 13.14 (4.79–35.41), n = 321 5.72 (2.11–15.34), n = 414  < 0.001
Inflammatory markers on admission, median (IQR)
 CRP, mg/L 5.15 (1.09–29.40), n = 476 4.00 (1.50–12.30), n = 1215 0.026
 WBC,  103 /µL 9.00 (6.70–11.85), n = 497 9.60 (7.44–12.27), n = 1390 0.001
ECG on admission
 ST-segment elevation 353 of 502 (70.3) 676 of 1503 (45.0)  < 0.001
Vital signs, mean (SD)
 Heart rate, beats/min 92.8 (21.8), n = 398 85.9 (20.0), n = 1319  < 0.001
 Systolic blood pressure, mm Hg 130.9 (30.7), n = 409 132.4 (28.1), n = 1339 0.36
 Diastolic blood pressure, mm Hg 77.6 (20.0), n = 404 77.2 (15.7), n = 1325 0.68
Hemodynamics, mean ± SD
 Left ventricular ejection fraction, %‡ 44.5 (13.3), n = 471 41.8 (11.2), n = 1485  < 0.001
Cardiovascular risk factors
 Hypertension 265 of 503 (52.7) 1078 of 1627 (66.3)  < 0.001
 Current smoking 75 of 494 (15.2) 289 of 1548 (18.7)  < 0.001
 Diabetes mellitus 91 of 503 (18.1) 222 of 1642 (13.5) 0.011
 Hypercholesterolemia 169 of 503 (33.6) 506 of 1594 (31.7) 0.44
Medication on admission
 Cardiovascular medication
  ACE-inhibitor or ARB 147 of 478 (30.8) 500 of 1268 (39.4) 0.001
  Beta-blocker 38 of 478 (7.9) 392 of 1268 (30.9)  < 0.001
  Calcium-channel antagonist 122 of 478 (25.5) 89 of 1236 (7.2)  < 0.001
  Statin 80 of 478 (16.7) 214 of 1236 (17.3) 0.78
Medication at discharge
 Cardiovascular medication
  ACE-inhibitor or ARB 199 of 448 (44.4) 1190 of 1471 (80.9)  < 0.001
  Beta-blocker 120 of 448 (26.8) 1153 of 1471 (78.4)  < 0.001
  Calcium-channel antagonist 125 of 462 (27.1) 134 of 1471 (9.1)  < 0.001
  Statin 112 of 448 (25.0) 749 of 1471 (50.9)  < 0.001
Acute cardiac care treatment
 Catecholamine use 71 of 502 (14.1) 170 of 1653 (10.3) 0.016
 Intra-aortic balloon pump 28 of 500 (5.6) 35 of 1652 (2.1)  < 0.001
In-hospital complications
 Cardiogenic shock 78 of 502 (15.5) 149 of 1660 (9.0)  < 0.001
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No large-scale study has been conducted so far to com-
pare TTS features between different ethnic groups. In a 
small study, Maekawa et al. found no significant difference 
in clinical characteristics between TTS patients in Japan 
(n = 12) and USA (n = 34) [17]. However, recent reports 
from Europe and Japan have demonstrated some differ-
ences in the demographic characteristics of those affected 
in these two regions: in Europe 85–90% of patients are 
women, and the mean age of patients is 65–70 years [13, 
23, 24], whereas in Japan, 75–85% are women, and the 
mean age of patients is 70–75 years [25–27]. These find-
ings were confirmed in the present study, the largest head-
to-head comparison to date. However, it should be noted 
that these disparities may reflect potential differences in 
patient selection and the older age of the general popula-
tion in Japan [28].
The present study found significant differences between 
the two cohorts in medications being used by the patients 
at admission. This difference may have partly affected in-
hospital outcomes. Japanese patients were more likely to 
be on regular calcium-channel antagonists at the TTS index 
event. These drugs are obviously contraindicated in patients 
with acute heart failure because of their negative inotropic 
effect [29] and their activation of the sympathetic nervous 
system [30]. In contrast, European TTS patients were more 
likely to receive beta-blockers, however, which have failed 
to show a beneficial effect on 1-year mortality [13]. Regu-
lar treatment with beta-blockers before admission may have 
protected patients with apical ballooning from left ventricu-
lar outflow tract obstruction [25]. These disparities in drug 
prescription seem to be due to different guidelines for the 
treatment of hypertension in these two regions [29, 31].
ACE angiotensin-converting-enzyme, ARB angiotensin-receptor blocker, BMI  body mass index, BNP brain natriuretic peptide, CRP C-reactive 
protein, ECG electrocardiogram, IQR interquartile range, SD standard deviation, TTS takotsubo syndrome, ULN upper limit of the normal, WBC 
white blood cell count
Data are presented as number (percentage) of patients unless otherwise indicated
*Including upper limits of the normal range for troponin T, high-sensitivity troponin T, and troponin I
† Including upper limits of the normal range for brain natriuretic peptide and the N-terminal of prohormone brain natriuretic peptide
‡ Data obtained during catheterization or echocardiography; if both results were available data from catheterization were used
Table 1  (continued)
Characteristic Japanese patients European patients p value
n = 503 n = 1670
 Death 41 (8.2) 53 (3.2)  < 0.001
Table 2  Two different models of multiple logistic regression Brier analysis and their scores
Bpm beats per minute, CI  confidence interval, HR  heart rate, LVEF  left ventricular ejection fraction, SBP systolic blood pressure, WBC  white 
blood cell count
Risk model I Risk model II
Odds ratio p value Odds ratio p value
(95% CI) (95% CI)
Intercept 0.04 (0.01 to 0.12)  < 0.001 0.02 (0.01 to 0.09)  < 0.001
Female sex 0.54 (0.27 to 1.09) 0.09 0.68 (0.33 to 1.39) 0.29
Physical stress 3.79 (1.90 to 7.55)  < 0.001 3.48 (1.73 to 6.99) 0.001
Emotional stress 0.53 (0.16 to 1.69) 0.28 0.63 (0.19 to 2.03) 0.44
Age 51–74 yr 0.36 (0.14 to 0.91) 0.030 0.30 (0.12 to 0.77) 0.013
Age ≥ 75 yr 0.91 (0.38 to 2.21) 0.83 0.67 (0.27 to 1.68) 0.39
HR > 94 bpm 1.85 (1.06 to 3.22) 0.030 1.58 (0.89 to 2.78) 0.12
SBP > 140 mmHg 1.01 (0.55 to 1.84) 0.99 1.00 (0.55 to 1.85) 0.99
LVEF > 45% 0.56 (0.28 to 1.12) 0.10 0.51 (0.25 to 1.01) 0.06
WBC > 10 ×  103 cells/
μL
2.25 (1.25 to 4.06) 0.007 2.35 (1.29 to 4.29) 0.005
Ethnicity (Japanese) – – 3.18 (1.76 to 5.73)  < 0.001
Brier score 0.038 0.037
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From a clinical perspective, the most important finding 
of the present study was the unanticipated worse in-hospital 
outcome in Japanese patients. We demonstrated by machine 
learning approach that the prognostic factors for in-hospital 
mortality were almost same in both cohorts; however, the 
relative importance of the factors varied. Physical stress was 
the most important prognostic factor for in-hospital mor-
tality in both cohorts. However, the prevalence of physical 
stressors was higher in Japanese patients and might have 
been responsible for the higher in-hospital mortality in this 
cohort. This observation is in line with our previous study 
demonstrating that physical triggers of TTS are independent 
predictors of poor in-hospital outcomes [12, 13]. Japanese 
patients were more likely to have cardiogenic shock than 
European patients. It is notable that in patients with cardio-
genic shock IABP was more often used in Japan compared 
to Europe (35.9 vs. 23.5%).
Although a role for genetics in TTS has not yet been fully 
uncovered, we examined whether ethnicity independently 
influences outcomes. Brinjikji et al., in their nation-wide 
study in the US, found that ethnicity was not associated with 
in-hospital mortality in TTS [32]; their study, however, had 
a very small proportion of Asian patients and included only 
patients located in the US without taking also geographic 
differences into account. Notably, we revealed in the pre-
sent study by use of three different statistical approaches 
that two different multiple logistic regression models (with 
and without ethnicity) had almost same accuracies of a 
risk prediction for in-hospital death. This observation can 
be interpreted that ethnicity, per se, does not have an addi-
tional impact on in-hospital death beyond that caused by 
differences of other clinical backgrounds. Nevertheless, 
patients with different ethnicities were enrolled from differ-
ent regions, and so differences between groups could be due 
to geographic and socioeconomic factors and regional differ-
ences in therapeutic strategies. Therefore, further studies are 
needed to clarify the impact of genetic factors on in-hospital 
outcomes of TTS patients.
Conclusions
This large-scale head-to-head comparative study provides 
important insights into ethnic disparities between Japanese 
and European TTS patients. Japanese patients are older and 
Fig. 2  Predictiveness curves of both models. Predictiveness curves of 
Model I (without ethnicity) and Model II (with ethnicity) were almost 
identical
Fig. 3  Decision trees. Decision trees for Japanese patients (a) and 
European patients (b). Presence of physical stressors was the most 
important prognostic factor for in-hospital mortality in the Japanese 
and European cohorts. The second most important prognostic factor 
was LVEF for Japanese patients, and the white blood cell count for 
European patients. LVEF left ventricular ejection fraction, SBP sys-
tolic blood pressure, WBC white blood cell count
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more likely to be male than European patients; they also 
have a significantly higher prevalence of physical triggers. 
Cardiogenic shock and in-hospital death are more common 
in Japanese patients. Ethnicity, per se, does not appear to 
have an additional impact on in-hospital mortality, beyond 
that caused by differences of other clinical backgrounds. 
Presence of physical stress is the most important prognostic 
factor in both Japanese and European patients. Thus, the 
worse in-hospital outcome in Japanese patients is mainly 
driven by the higher prevalence of physical triggers in this 
cohort.
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